Anavex Life Sciences Corp. (AVXL) vs Veraxa Biotech Holding AG (VRXA)

A side-by-side comparison of Anavex Life Sciences Corp. and Veraxa Biotech Holding AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AVXL

Anavex Life Sciences Corp.

$148M

$1.60HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

VRXA

Veraxa Biotech Holding AG

$153M

$1.08HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AVXL vs VRXA

growth of $100 · dividends reinvested · last 1y

AVXL -46.1% (-46.1%/yr)VRXA -90.8% (-90.8%/yr)AVXL compounded faster over this window

Log scale — wide-divergence pair

AVXL VRXA

Metrics side by side

Total return (annualized)

Metric	AVXL	VRXA
Total return (1Y)	-83.29%	N/A
Total return CAGR (3Y)	-36.38%	N/A
Total return CAGR (5Y)	-37.74%	N/A
Total return CAGR (10Y)	-7.93%	N/A

VRXA is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full AVXL analysis Full VRXA analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.